Insulet (PODD) EBITDA Margin Growth (5y) (2015 - 2026)
Insulet (PODD) EBITDA Margin Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.52 Bn | 175.22 Bn | 6.27 Bn |
| 2 | Stryker | 128.96 Bn | 126.09 Bn | 3.81 Bn |
| 3 | Medtronic | 107.99 Bn | 98.77 Bn | 6.41 Bn |
| 4 | Boston Scientific | 67.76 Bn | 66.31 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.09 Bn | 44.41 Bn | 1.29 Bn |
| 6 | Dexcom | 28.30 Bn | 27.18 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 27.89 Bn | 25.61 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 27.02 Bn | 26.45 Bn | - |
| 9 | Koninklijke Philips | 23.98 Bn | 20.86 Bn | 2.07 Bn |
| 10 | Insulet | 11.56 Bn | 11.07 Bn | 529.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 957.00 |
| Dec 31, 2025 | 2,163.00 |
| Sep 30, 2025 | 649.00 |
| Jun 30, 2025 | 650.00 |
| Mar 31, 2025 | 1,182.00 |
| Dec 31, 2024 | 965.00 |
| Sep 30, 2024 | 735.00 |
| Jun 30, 2024 | 687.00 |
| Mar 31, 2024 | 831.00 |
| Dec 31, 2023 | 1,105.00 |
| Sep 30, 2023 | 812.00 |
| Jun 30, 2023 | 436.00 |
| Dec 31, 2022 | 694.00 |
| Sep 30, 2022 | -83.00 |
| Jun 30, 2022 | -586.00 |
| Mar 31, 2022 | 1,805.00 |
| Dec 31, 2021 | 2,014.00 |
| Sep 30, 2021 | 1,032.00 |
| Jun 30, 2021 | 1,159.00 |
| Mar 31, 2021 | 1,594.00 |